keyword
MENU ▼
Read by QxMD icon Read
search

Biochemical relapse of prostate cancer

keyword
https://www.readbyqxmd.com/read/28807532/multicenter-evaluation-of-biochemical-relapse-free-survival-outcomes-for-intraoperatively-planned-prostate-brachytherapy-using-an-automated-delivery-system
#1
Kevin Martell, Siraj Husain, Daniel Taussky, Steve Angyalfi, Guila Delouya, Philippe Després, Luc Beaulieu, Andre-Guy Martin, Eric Vigneault
PURPOSE: To report biochemical recurrence in prostate cancer treated with intraoperatively planned low-dose-rate prostate brachytherapy using an automated delivery system (IO-LDRB). METHODS AND MATERIALS: Between 2003 and 2013, 2608 patients from 3 centers were treated with IO-LDRB as single-modality treatment for low or low-tier intermediate-risk prostate cancer. Databases from the 3 centers have been analyzed. These independent databases were collected prospectively...
June 6, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28806257/orbital-hemangiopericytoma-in-68ga-prostate-specific-membrane-antigen-hbed-cc-pet-ct
#2
Jochen Hammes, Carsten Kobe, Ute Hilgenberg, Wolfgang E Lieb, Alexander Drzezga
A 76-year-old man with biochemical relapse of prostate cancer underwent Ga-prostate-specific membrane antigen PET/CT. Besides a local lymph node metastasis, a nodular structure inside the left orbit caudal to the optic nerve showed increased uptake. A metastasis in this location is unlikely. The subsequently performed MRI showed the structure being T1 hypointense, T2 indifferent, and strongly gadolinium contrast agent enhancing. Histopathologic examination after surgical removal identified the tumor as hemangiopericytoma, which rarely occurs in the orbit...
August 12, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28800286/clinical-pet-imaging-in-prostate-cancer
#3
Kathryn L Wallitt, Sairah R Khan, Suraiya Dubash, Henry H Tam, Sameer Khan, Tara D Barwick
Prostate cancer is the second most common cancer in men worldwide, with a wide spectrum of biologic behavior ranging from indolent low-risk disease to highly aggressive castration-resistant prostate cancer. Conventional imaging with computed tomography, magnetic resonance imaging, and bone scintigraphy is limited for the detection of nodal disease and distant bone metastases. In addition, advances in the available therapeutic options, both localized and systemic, drive the requirement for precise diagnostic and prognostic tools to refine the individual therapeutic approach at various times in the management of patients with prostate cancer...
August 11, 2017: Radiographics: a Review Publication of the Radiological Society of North America, Inc
https://www.readbyqxmd.com/read/28795303/the-feasibility-of-prostate-specific-membrane-antigen-positron-emission-tomography-psma-pet-ct-guided-radiotherapy-in-oligometastatic-prostate-cancer-patients
#4
O C Guler, B Engels, C Onal, H Everaert, R Van den Begin, T Gevaert, M de Ridder
BACKGROUND: To investigate the efficacy and toxicity of 68Ga-PSMA-HBED-CC ((68)Ga-PSMA) PET-CT-guided RT in the treatment of oligometastatic prostate cancer retrospectively. METHODS: A total of 23 prostate cancer patients with biochemical relapse, of which 13 were castration sensitive (CS) and 10 castration resistant (CR), were treated with intensity-modulated and image-guided RT (IMRT-IGRT) on ≤3 metastases detected by (68)Ga PSMA PET-CT. Androgen deprivation therapy was continued in CR patients...
August 9, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/28791252/prostate-specific-antigen-5-years-following-stereotactic-body-radiation-therapy-for-low-and-intermediate-risk-prostate-cancer-an-ablative-procedure
#5
Shaan Kataria, Harsha Koneru, Shan Guleria, Malika Danner, Marilyn Ayoob, Thomas Yung, Siyuan Lei, Brian T Collins, Simeng Suy, John H Lynch, Thomas Kole, Sean P Collins
BACKGROUND: Our previous work on early PSA kinetics following prostate stereotactic body radiation therapy (SBRT) demonstrated that an initial rapid and then slow PSA decline may result in very low PSA nadirs. This retrospective study sought to evaluate the PSA nadir 5 years following SBRT for low- and intermediate-risk prostate cancer (PCa). METHODS: 65 low- and 80 intermediate-risk PCa patients were treated definitively with SBRT to 35-37.5 Gy in 5 fractions at Georgetown University Hospital between January 2008 and October 2011...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/28764689/heterogeneity-in-high-risk-prostate-cancer-treated-with-high-dose-radiation-therapy-and-androgen-deprivation-therapy
#6
Daniel N Cagney, Mary Dunne, Carmel O'Shea, Marie Finn, Emma Noone, Martina Sheehan, Lesley McDonagh, Lydia O'Sullivan, Pierre Thirion, John Armstrong
BACKGROUND: Our aim was to assess the heterogeneity of high-risk (HR) prostate cancer managed with high-dose external beam radiotherapy (EBRT) with androgen deprivation therapy (ADT). METHODS: We identified 547 patients who were treated with modern EBRT from 1997 to 2013, of whom 98% received ADT. We analyzed biochemical relapse-free survival (bRFS) and distant metastases-free survival (DMFS). RESULTS: Median EBRT dose was 74 Gy, and median ADT duration was 8 months...
August 1, 2017: BMC Urology
https://www.readbyqxmd.com/read/28754301/high-dose-rate-brachytherapy-boost-for-prostate-cancer-comparison-of-three-different-fractionation-schemes
#7
Alexander T Falk, Sylvain Demontoy, Emmanuel Chamorey, Marie-Eve Chand, Mathieu Gautier, David Azria, Sara Zaki, Daniel Chevallier, Daniel Lam Cham Kee, Jean-Michel Hannoun-Lévi
PURPOSE: Dose escalation for prostate cancer can be achieved with a combination of external beam radiotherapy (EBRT) and brachytherapy (BT) boost to increase local control. For high-dose-rate (HDR)-BT, optimal fractionation remains under debate. The objective was to assess the clinical outcome of three schemes of HDR-BT boost. METHODS AND MATERIALS: Retrospective single institution data collection was performed. Patients received 46 Gy EBRT then an HDR-BT boost: 3 × 6 Gy, 2 × 9 Gy, or 1 × 14 Gy...
July 25, 2017: Brachytherapy
https://www.readbyqxmd.com/read/28752514/the-impact-of-multifocal-perineural-invasion-on-biochemical-recurrence-and-timing-of-adjuvant-androgen-deprivation-therapy-in-high-risk-prostate-cancer-following-radical-prostatectomy
#8
Guangxi Sun, Rui Huang, Xingming Zhang, Pengfei Shen, Jing Gong, Jinge Zhao, Jiandong Liu, Qidun Tang, Kunpeng Shu, Xiaoxue Yin, Ni Chen, Hao Zeng
BACKGROUND: Perineural invasion (PNI) is a distinct pathologic entity and a recognized source of tumor spread. However, the role of PNI in high-risk prostate cancer (PCa) has not been explored. The aims of the study were to investigate the impact of PNI on biochemical recurrence (BCR) and optimal timing of adjuvant androgen-deprivation therapy (ADT) after radical prostatectomy (RP). METHODS: A total of 265 prostatectomies, median follow-up 45 months, were assessed for the presence and intensity of PNI (unifocal and multifocal) in RP specimens...
July 27, 2017: Prostate
https://www.readbyqxmd.com/read/28749171/prospective-evaluation-of-a-specific-technique-of-sexual-function-preservation-in-external-beam-radiotherapy-for-prostate-cancer
#9
Hamza Samlali, Corina Udrescu, Ariane Lapierre, Ciprian Enachescu, Alain Ruffion, Patrice Jalade, Olivier Chapet
OBJECTIVES: Sexual preservation is an important issue in the treatment of localized prostate cancer. A technique of irradiation was developed to better preserve this function and has been evaluated. METHODS: Eleven patients, with no erectile dysfunction (ED), were treated with daily IMRTIGRT (total dose: 76-78 Gy). The pudendal arteries, penile bulb and cavernous body were delineated on the planning CT scan. The doses to these structures (with a 5 mm margin) were optimized to be as low as possible...
July 27, 2017: British Journal of Radiology
https://www.readbyqxmd.com/read/28725583/positron-emission-tomography-pet-in-primary-prostate-cancer-staging-and-risk-assessment
#10
REVIEW
Sandra Bednarova, Maria L Lindenberg, Maria Vinsensia, Chiara Zuiani, Peter L Choyke, Baris Turkbey
Prostate cancer (PCa) is one of the few neoplasms that are not well served by 18F-Fluorodeoxyglucose (FDG) positron emission tomography (PET). As a result, a number of PET tracers have been developed to target particular biological features of PCa. Such agents can be used for diagnosis, staging, identification of biochemical recurrence (BCR) and evaluation of metastatic disease. Here, we focus on primary disease and local staging. To date, magnetic resonance imaging (MRI) has proven superior to PET in the imaging of primary PCa...
June 2017: Translational Andrology and Urology
https://www.readbyqxmd.com/read/28723518/mid-term-outcomes-following-salvage-lymph-node-dissection-for-prostate-cancer-nodal-recurrence-status-post-radical-prostatectomy
#11
Fabio Zattoni, Avinash Nehra, Christopher R Murphy, Laureano Rangel, Lance Mynderse, Val Lowe, Eugene Kwon, R Jeffrey Karnes
BACKGROUND: Patients with oligometastatic prostate cancer lymph node recurrence can be treated with many options including salvage lymph node dissection (sLND). OBJECTIVE: Evaluation of outcomes of sLND and identification of clinicopathologic features in predicting further biochemical and radiological relapse after sLND for prostate cancer. DESIGN, SETTING, AND PARTICIPANTS: Between November 1, 2009 and March 31, 2015, 117 patients with biochemical recurrence (BCR) after radical prostatectomy (RP) underwent sLND by a single surgeon after a standardized 11C-choline positron emission tomography/computed tomography...
December 2016: European Urology Focus
https://www.readbyqxmd.com/read/28674394/genetic-association-analysis-of-the-rtk-erk-pathway-with-aggressive-prostate-cancer-highlights-the-potential-role-of-ccnd2-in-disease-progression
#12
Yang Chen, Qin Zhang, Qiuyan Wang, Jie Li, Csilla Sipeky, Jihan Xia, Ping Gao, Yanling Hu, Haiying Zhang, Xiaobo Yang, Haitao Chen, Yonghua Jiang, Yuehong Yang, Ziting Yao, Yinchun Chen, Yong Gao, Aihua Tan, Ming Liao, Johanna Schleutker, Jianfeng Xu, Yinghao Sun, Gong-Hong Wei, Zengnan Mo
The RTK/ERK signaling pathway has been implicated in prostate cancer progression. However, the genetic relevance of this pathway to aggressive prostate cancer at the SNP level remains undefined. Here we performed a SNP and gene-based association analysis of the RTK/ERK pathway with aggressive prostate cancer in a cohort comprising 956 aggressive and 347 non-aggressive cases. We identified several loci including rs3217869/CCND2 within the pathway shown to be significantly associated with aggressive prostate cancer...
July 3, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28667448/adjuvant-versus-salvage-radiotherapy-in-prostate-cancer-multi-institutional-retrospective-analysis-of-the-spanish-recap-database
#13
A Hervás, A Gómez-Caamaño, M Casaña, A Gómez-Iturriaga, J Pastor, J Jove, J L Mengual, C Gónzalez-San Segundo, J Muñoz
PURPOSE: To compare adjuvant radiotherapy (ART) to salvage radiotherapy (SRT) after radical prostatectomy (RP) in a cohort of prostate cancer (PCa) patients. The primary aim was to comparatively assess 2- and 5-year biochemical relapse-free survival (BRFS). A secondary aim was to identify predictors of survival. PATIENTS AND METHODS: Data were acquired from the RECAP database, a population-based prostate cancer registry in Spain. Inclusion criteria included RP (with or without lymphadenectomy) followed by ART or SRT...
June 30, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/28666552/single-dose-high-dose-rate-brachytherapy-compared-to-two-and-three-fractions-for-locally-advanced-prostate-cancer
#14
Peter Hoskin, Ana Rojas, Peter Ostler, Robert Hughes, Roberto Alonzi, Gerry Lowe
BACKGROUND: Single-dose high-dose-rate brachytherapy (HDR-BT), in a Phase-II study, was compared to two or three fractions in intermediate and high-risk localized prostate cancer. PATIENTS AND METHODS: 293 patients received 1×19Gy or 1×20Gy (A=49), 2×13Gy (B=138), or 3×10.5Gy (C=106) and assessed with prospective measures of serum PSA, late genitourinary (GU) and gastrointestinal (GI) morbidity using RTOG scales and the International Prostate Symptom Score (IPSS)...
June 27, 2017: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/28642046/prostate-specific-antigen-percentage-an-early-predictive-tool-after-iodine-125-interstitial-brachytherapy-for-prostate-cancer
#15
Mauro Paoluzzi, Andrea Losa, Valentina Cerboneschi, Caterina Colosimo, Nicola Fontana, Paola Mangili, Marcello Mignogna, Luciano Nava, Valentina Ravaglia
BACKGROUND: After interstitial prostate iodine-125 brachytherapy (BT), prostate-specific antigen (PSA) evolution in time could predict overall biochemical relapse, but, considering the single patient, it is influenced by the presentation PSA amount and by the prostatic volume. It is also challenging to differentiate a PSA bounce from a biochemical relapse. PURPOSE: To determine the usefulness of PSA percentage (PP) defined as the rate between PSA presented by a patient at time "t" and the PSA that the same patient had presented at the time of diagnosis (t0) assumed as 100% in predicting biochemical relapse and in differentiating them from PSA Bounces...
June 19, 2017: Brachytherapy
https://www.readbyqxmd.com/read/28637799/-68-ga-psma-pet-ct-and-volumetric-morphology-of-pet-positive-lymph-nodes-stratified-by-tumor-differentiation-of-prostate-cancer
#16
Maria Vinsensia, Peter L Choyke, Boris Hadaschik, Tim Holland-Letz, Jan Moltz, Klaus Kopka, Isabel Rauscher, Walter Mier, Markus Schwaiger, Uwe Haberkorn, Tobias Maurer, Clemens Kratochwil, Matthias Eiber, Frederik Giesel
(68)Ga prostate specific membrane antigen (PSMA) positron emission tomography (PET)/computer tomography (CT) is a new method to detect early nodal metastases in patients with biochemical relapse of prostate cancer (PCa). In this retrospective investigation the dimensions, volume, localization and maximum standardized uptake value (SUVmax) of nodes identified by (68)Ga-PSMA were correlated to their Gleason score (GS) at diagnosis. Methods: All PET/CT images were acquired 60±10 min after intravenous injection of (68)Ga-PSMA (mean dose 176 MBq)...
June 21, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28623852/frusemide-aids-diagnostic-interpretation-of-68-ga-psma-positron-emission-tomography-ct-in-men-with-prostate-cancer
#17
Niall Fennessy, Jonathan Lee, Jane Shin, Bao Ho, Syed Aman Ali, Royce Paschkewitz, Louise Emmett
INTRODUCTION: (68) Ga-PSMA positron emission tomography-computed tomography (PET/CT) is useful for both staging and assessment of biochemical relapse in men with prostate cancer. Renal excretion of (68) Ga-PSMA can lead to difficulties in scan interpretation, particularly in the pelvis. We evaluated if intravenous Frusemide at the time of (68) Ga-PSMA injection reduces excreted activity artefact and improves diagnostic certainty. METHODS: Sixty-two men with prostate cancer undergoing clinically indicated (68) Ga-PSMA PET/CT were prospectively included, 30 men receiving Frusemide at the time of radiotracer injection...
June 17, 2017: Journal of Medical Imaging and Radiation Oncology
https://www.readbyqxmd.com/read/28622770/intensity-modulated-radiation-therapy-from-70gy-to-80gy-in-prostate-cancer-six-year-outcomes-and-predictors-of-late-toxicity
#18
Maria Jolnerovski, Julia Salleron, Véronique Beckendorf, Didier Peiffert, Anne-Sophie Baumann, Valérie Bernier, Sandrine Huger, Vincent Marchesi, Ciprian Chira
OBJECTIVE: To report grade ≥2 overall late rectal and urinary toxicities in patients (pts) with prostate cancer treated by intensity-modulated radiotherapy (IMRT) at 3 dose-levels. Identify predictors of radiation toxicity and report biochemical progression free survival (bPFS). METHODS: A total of 277 pts were treated with 70Gy (10.8%), 74Gy (63.9%) and 80 Gy (25.3%) using IMRT without pelvic irradiation were analyzed. Short or long-course androgen deprivation therapy (ADT) was allowed in 46...
June 16, 2017: Radiation Oncology
https://www.readbyqxmd.com/read/28620579/delineation-of-the-prostate-bed-the-invisible-target-is-still-an-issue
#19
Igor Latorzeff, Paul Sargos, Geneviève Loos, Stéphane Supiot, Stéphane Guerif, Christian Carrie
For pathological high-risk prostate cancer, adjuvant irradiation has shown a survival benefit. Phase III studies have highlighted that half men would face biochemical relapse and would be candidate for radiotherapy at adjuvant or salvage times. Despite at least four published international contouring guidelines from different collaborative groups, discrepancies remain for volumes, delineation, and margins to be considered in order to optimize radiotherapy planning. This article from "Groupe d'Etude des Tumeurs UroGénitales (GETUG)" members will focus on controversies to help clinicians to create best volume delineation for adjuvant or salvage post prostatectomy radiotherapy...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/28607544/analysis-of-fascin-1-in-relation-to-gleason-risk-classification-and-nuclear-ets-related-gene-status-of-human-prostate-carcinomas-an-immunohistochemical-study-of-clinically-annotated-tumours-from-the-wales-cancer-bank
#20
Matthew T Jefferies, Christopher S Pope, Howard G Kynaston, Alan R Clarke, Richard M Martin, Josephine C Adams
Although prostate-specific antigen (PSA) testing can identify early-stage prostate cancers, additional biomarkers are needed for risk stratification. In one study, high levels of the actin-bundling protein, fascin-1, were correlated with lethal-phase, hormone-refractory prostate cancer. Analyses of independent samples are needed to establish the value of fascin-1 as a possible biomarker. We examined fascin-1 by immunohistochemistry in tumour specimens from the Wales Cancer Bank in comparison with nuclear-located ETS-related gene (ERG), an emerging marker for aggressive prostate cancer...
2017: Biomarkers in Cancer
keyword
keyword
111181
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"